News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,816 Results
Type
Article (40008)
Company Profile (250)
Press Release (664557)
Multimedia
Podcasts (58)
Webinars (14)
Section
Business (204274)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81139)
Employer Resources (172)
FDA (16249)
Job Trends (14886)
News (345497)
Policy (32606)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1440)
Antibody-drug conjugate (ADC) (151)
Approvals (16245)
Artificial intelligence (308)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (364)
Cancer (2855)
Cardiovascular disease (212)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (497)
Cervical cancer (22)
Clinical research (66845)
Collaboration (1011)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2624)
CRISPR (56)
C-suite (324)
Cystic fibrosis (112)
Data (2991)
Decentralized trials (2)
Denatured (20)
Depression (60)
Diabetes (346)
Diagnostics (6423)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (137)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87445)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113735)
Executive appointments (845)
FDA (17891)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (928)
Gene editing (129)
Generative AI (22)
Gene therapy (372)
GLP-1 (780)
Government (4500)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2795)
Inflammatory bowel disease (148)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3636)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (491)
Leadership (18)
Legal (7929)
Liver cancer (79)
Lung cancer (399)
Lymphoma (208)
Machine learning (11)
Management (58)
Manufacturing (383)
MASH (90)
Medical device (13460)
Medtech (13465)
Mergers & acquisitions (19576)
Metabolic disorders (847)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2115)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (427)
Opinion (217)
Ovarian cancer (101)
Pain (105)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (296)
Patient recruitment (163)
Peanut (50)
People (57681)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20827)
Phase II (29442)
Phase III (21916)
Pipeline (1626)
Policy (198)
Postmarket research (2563)
Preclinical (8869)
Press Release (64)
Prostate cancer (139)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (457)
Real estate (5917)
Recruiting (66)
Regulatory (22625)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (156)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (36)
Vaccines (778)
Venture capital (53)
Weight loss (256)
Women's health (47)
Worklife (16)
Date
Today (65)
Last 7 days (366)
Last 30 days (1865)
Last 365 days (31227)
2025 (16713)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38203)
Australia (6232)
California (7426)
Canada (2355)
China (669)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82100)
Florida (1115)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (361)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1019)
Massachusetts (5516)
Michigan (246)
Minnesota (449)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2070)
New Mexico (28)
New York (2082)
North Carolina (1078)
North Dakota (8)
Northern California (3269)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1609)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2777)
Tennessee (126)
Texas (1120)
United States (27509)
Utah (219)
Virginia (184)
Washington D.C. (72)
Washington State (630)
West Virginia (4)
Wisconsin (66)
704,816 Results for "glycomine inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year
The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a rare disease that affects the entire body and produces a wide range of symptoms.
April 16, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG
April 16, 2025
·
3 min read
Press Releases
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors
October 10, 2024
·
2 min read
Biotech Bay
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG
Glycomine, Inc. announced the presentation of summary findings from its ongoing Phase 2 clinical study (GLM101-002) in adult patients with PMM2-CDG at the Rare Disease Day 2024 Symposium, CDG Scientific and Family Conference, that took place March 1-3 in San Diego.
March 4, 2024
·
3 min read
Business
Glycomine Appoints Dr. Rose Marino Chief Medical Officer
Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious orphan diseases, announced the appointment of Rose Marino, M.D. as Chief Medical Officer.
October 12, 2023
·
2 min read
Drug Development
Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
Glycomine, Inc. announced the first pediatric patient has been dosed in a multi-center open-label Phase 2 study of GLM101.
December 11, 2023
·
2 min read
Press Releases
Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG
September 18, 2024
·
2 min read
Biotech Bay
Data from Glycomine’s Ongoing Natural History Study Provides Insight into Clinical Measures and Biomarkers for PMM2-CDG
Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium taking place August 29 to September 1 in Jerusalem.
August 30, 2023
·
3 min read
Biotech Bay
Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG
Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the American Society for Human Genetics (ASHG) 2023 Annual Meeting taking place in Washington, DC.
November 2, 2023
·
3 min read
Drug Development
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
Glycomine, Inc. today announced that the first patient has been dosed in a multi-center open-label Phase 2 study (ClinicalTrials.gov Identifier: NCT05549219) of GLM101, a targeted mannose-1-phosphate replacement therapy, in adult patients with phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG).
January 9, 2023
·
2 min read
1 of 70,482
Next
